An implementation science approach for developing and implementing a dietitian-led model of care for gestational diabetes: a pre-post study

Table 4 Pharmacotherapy use and maternal and infant outcomes for the pre-and-post intervention groups

Maternal and infant outcomes	Pre-Intervention (n = 125)	Post-Intervention (n = 120)	Unadjusted P-Value	Adjusted P-Value*	OR (CI)**
Binary outcomes
Requiring any pharmacotherapy, n (%)	46 (37%)	56 (47%)	0.10	0.15	1.53 (0.86–2.81)
Metformin	20 (16%)	10 (8.3%)
Insulin	14 (11%)	33 (28%)
Metformin + insulin	12 (10%)	14 (12%)
Large-for-gestational age, n (%)	10 (8.0%)	12 (10.1%)	0.57	0.56	1.30 (0.54–3.15)
Small-for-gestational age, n (%)	10 (8.0%)	12 (10.1%)	0.57	0.81	1.12 (0.45–2.79)
Continuous outcomes
Gestational age for pharmacotherapy, mean (SD), weeks	30.1 (4.7)	27.8 (6.8)	0.05
Infant birthweight, mean (SD), grams	3352 (499)	3290 (470)	0.32

*Confounders in logistic regression modelling: Requiring any pharmacotherapy (maternal age > 30 years, pre-pregnancy BMI > 30 kg/m², previous GDM, diagnostic fasting > 5.2, early diagnosis < 24 weeks gestation, family history of type 2 diabetes mellitus); large-for-gestational age (pre-pregnancy BMI > 30 kg/m²); small -for-gestational age (smoking, during pregnancy)
** OR, 95% confidence intervals from logistic regression models using the pre-intervention as the reference group

ISSN: 1471-2393